Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineAmivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC

Combination Therapy in EGFR-Mutated NSCLC: Potential to Extend Progression-Free Survival and Response Duration

A recent phase 3 randomized trial evaluated the efficacy of amivantamab plus lazertinib compared to osimertinib in patients with previously untreated, advanced non–small-cell lung cancer (NSCLC) harboring EGFR mutations. The study aimed to determine if the combination therapy could offer superior progression-free survival and response duration over the current standard treatment with osimertinib.

Study Design:

  • Participants: 1074 patients with EGFR-mutated (exon 19 deletion or L858R) locally advanced or metastatic NSCLC.
  • Randomization: Patients were assigned in a 2:2:1 ratio to receive either amivantamab–lazertinib (429 patients), osimertinib (429 patients), or lazertinib (216 patients).
  • Primary Endpoint: Progression-free survival, assessed by blinded independent central review.

Key Findings:

  • Progression-Free Survival: Median of 23.7 months in the amivantamab–lazertinib group versus 16.6 months in the osimertinib group (hazard ratio for disease progression or death, 0.70; P<0.001).
  • Objective Response Rate: 86% in the amivantamab–lazertinib group versus 85% in the osimertinib group.
  • Response Duration: Median response duration of 25.8 months with amivantamab–lazertinib versus 16.8 months with osimertinib.
  • Overall Survival: Interim analysis showed a hazard ratio for death of 0.80 (95% CI, 0.61 to 1.05) favoring amivantamab–lazertinib.
  • Adverse Events: Predominantly EGFR-related toxic effects; treatment discontinuation due to adverse events was 10% for amivantamab–lazertinib and 3% for osimertinib.

HCN Medical Memo
The phase 3 study demonstrates that amivantamab plus lazertinib offers significant improvements in progression-free survival and response duration over osimertinib in EGFR-mutated advanced NSCLC. This combination therapy presents a viable first-line treatment option, potentially altering the clinical approach to managing these patients.

More on Lung Cancer

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form